Companies: 10,795·Total market cap: $144.5T
ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACADNASDAQHealthcare● Active
$21.56
$-0.16(-0.74%)
Market Cap$3.7B
P/E Ratio
52W High$28.35
52W Low$19.69
Overview

ACADIA Pharmaceuticals Inc. (ACAD) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ACAD · as of Jun 8, 2026

Key Statistics

EPS (TTM)$2.23acad eps ttm · acad earnings per shareEarnings history
PE Ratio (TTM)9.7×acad pe ratio ttm · acad price to earningsPE Ratio deep dive
Revenue (TTM)$1.1Bacad revenue ttm · acad annual revenueFull revenue history
Dividend YieldNo Dividenddoes acad pay dividends · acad dividend yieldDividend history
Shares Outstanding169.3Macad shares outstanding · acad floatShares outstanding history
Next EarningsAug 5, 2026Est.acad earnings date · acad next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$1.07B▲ +11.87% YoY
202320242025
acadia pharmaceuticals inc. revenue · acad revenue 2025
FY 2025Net Income$391.0M▲ +72.66% YoY
202320242025
acadia pharmaceuticals inc. net income · acad profit 2025
FY 2025EPS$2.32▲ +69.34% YoY
202320242025
acad eps · acadia pharmaceuticals inc. earnings per share 2025
TTM:Revenue: $1.10BNet Income: $375.6MEPS: $2.23View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy37 analystsis acad a buy · acad analyst rating
Strong Buy
0
Buy
26
Hold
10
Sell
1
Strong Sell
0
12-Month Price Target
$29.00Low
$21.56Current
$34.78Avg Target61.32% upside
$40.00High
acad price target · acad 12 month forecast

Total: 37 · Buy rate: 70.3%

The ACAD analyst consensus is Buy, based on ratings from 37 Wall Street analysts over the past 3 months. The average 12-month price target is $34.78, representing +61.32% upside from the current price of $21.56.

Stock Performance

Full History
1D-0.74%
1W+3.31%
1M-3.75%
3M-2.71%
YTD-19.28%
1Y-3.32%
5Y-18.86%

About ACADIA Pharmaceuticals Inc.

CEOCatherine E. Owen Adams
IPO DateMay 27, 2004
Employees653
CountryUS

ACADIA Pharmaceuticals Inc. a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.…

what is acadia pharmaceuticals inc. · acad stock overview · acadia pharmaceuticals inc. company profile · who is acadia pharmaceuticals inc. ceo · acad NASDAQ · acadia pharmaceuticals inc. headquarters · acadia pharmaceuticals inc. business segments

About Stock Overview & Key Data

ACADIA Pharmaceuticals Inc. (ACAD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 27, 2004. As of the latest trading session, ACAD stock price is $21.56, with a market capitalization of $3.7B. The stock has returned -3.32% over the past 12 months and -19.28% year-to-date.

According to 37 Wall Street analysts, the consensus rating for ACADIA Pharmaceuticals Inc. stock is Buy, with an average 12-month price target of $34.78. In fiscal year 2025, ACADIA Pharmaceuticals Inc. reported revenue of $1.1B and net income of $391.0M. For detailed data — including ACADIA Pharmaceuticals Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, ACADIA Pharmaceuticals Inc. (ACAD) stock price is $21.56. The stock is traded on NASDAQ under the ticker symbol ACAD. The 52-week range is $19.69 – $28.35.

ACAD stock priceACAD quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice